+375.7%
KORU vs GSK
+21.8%
+353.9%
-80.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.0% | 0.0% | +9.0% | +9.0% |
| 7D | -1.7% | -3.5% | +1.8% | -2.6% |
| 30D | +13.5% | -3.4% | +17.0% | +12.7% |
| 3M | -45.2% | -8.1% | -37.1% | -45.5% |
| 6M | +17.1% | -11.1% | +28.3% | +21.1% |
| YTD | +154.1% | +0.7% | +153.4% | +161.3% |
| 1Y | +375.7% | +20.1% | +355.5% | +381.2% |
| All | +375.7% | +21.8% | +353.9% | +381.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling